PROKIDNEY CORP. 4

Chief Technical Officer Kenneth Thomas Locke received an employee stock option award for 750,000 shares of ProKidney Corp. Class A Common Stock at an exercise price of $1.89 per share.

On July 1, 2026, ProKidney Corp. Chief Technical Officer Kenneth Thomas Locke received a grant of employee stock options covering 750,000 shares of Class A Common Stock at an exercise price of $1.89 per share, with no shares acquired upon grant and vesting scheduled at 25% on the first anniversary of July 1, 2026 and the remaining 75% in substantially equal monthly installments over the following 36 months, contingent on continued employment. This award represents a new equity incentive position rather than an open-market transaction and results in derivative ownership of 750,000 options, which if fully exercised would represent an aggregate exercise cost of approximately $1.42 million and a notional exposure to the underlying common stock of the same share amount. No concurrent sales or purchases of common stock were reported in this filing.

Filing Facts

CIK

1850270

Ticker

PROK

Form

4

Source Type

sec

Accession

0001193125-26-296160

Alert Tier

6